Twist Bioscience
Twist manufactures synthetic DNA on a silicon platform and in 2026 launched Complex Genes (early access) for challenging repeat-rich sequences, feeding every downstream build.
- Country
- United States
Commercial
Public (NYSE)
ISO 9001
Coverage
| CN | EU | US | |
|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ |
| foundries-design | ✓ | ✓ | ✓ |
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsepafdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DNA synthesis & gene foundry | foundries-design | Low | → |
| Genomics & DNA design | bioinformatics-omics | Medium | → |
| iGEM infrastructure, BioBricks and standard genetic parts | foundries-design | Low | → |
| Synthetic biology | genome-engineering | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.